title: Rationale for the use of upfront whole brain irradiation in patients with brain metastases from breast cancer.
abstract: Breast cancer is the second most common cause of brain metastases and deserves particular attention in relation to current prolonged survival of patients with metastatic disease. Advances in both systemic therapies and brain local treatments (surgery and stereotactic radiosurgery) have led to a reappraisal of brain metastases management. With respect to this, the literature review presented here was conducted in an attempt to collect medical evidence-based data on the use of whole-brain radiotherapy for the treatment of brain metastases from breast cancer. In addition, this study discusses here the potential differences in outcomes between patients with brain metastases from breast cancer and those with brain metastases from other primary malignancies and the potential implications within a treatment strategy.
authors.affiliation: Department of Radiation Oncology, Institut Paoli Calmettes, Marseille 13009, France. talleta@ipc.unicancer.fr.
authors.forename: Agnes V
authors.initials: AV
authors.lastname: Tallet
authors.affiliation: Department of Radiation Oncology and INSERM U896, CRLC Val d'Aurelle, Montpellier 34000, France. David.Azria@icm.unicancer.fr.
authors.forename: David
authors.initials: D
authors.lastname: Azria
authors.affiliation: Breast Unit, Department of Medical Oncology, Oscar Lambret Center, Lille Cedex 59020, France. le_rhun@yahoo.fr.
authors.forename: Emilie
authors.initials: E
authors.lastname: Le Rhun
authors.affiliation: Multidisciplinary Oncology and Therapeutic Innovations Department & Centre Investigation Clinique, Aix Marseille University-Assistance Publique Hôpitaux de Marseille, Marseille 13011, France. Fabrice.BARLESI@ap-hm.fr.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Barlesi
authors.affiliation: Department of Neurology, Hopital Avicenne, Assistance Publique des Hopitaux de Paris, Bobigny 93000, France. antoine.carpentier@avc.aphp.fr.
authors.forename: Antoine F
authors.initials: AF
authors.lastname: Carpentier
authors.affiliation: Department of Medical Oncology, Institut Paoli Calmettes, Marseille 13009, France. goncalvesa@ipc.unicancer.fr.
authors.forename: Antony
authors.initials: A
authors.lastname: Gonçalves
authors.affiliation: Department of Radiation Oncology and Department of Neuro-Oncology, Pitié-Salpétrière Hospital, Paris 75013, France. sophie.taillibert@gmail.com.
authors.forename: Sophie
authors.initials: S
authors.lastname: Taillibert
authors.affiliation: Department of Radiation Oncology, Institut Gustave Roussy University Hospital, Villejuif 94805, France. Frederic.DHERMAIN@gustaveroussy.fr.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Dhermain
authors.affiliation: Department of Medical Oncology, GH Pitié-Salpêtrière, Université Paris 6, Paris 75013, France. jean-philippe.spano@psl.aphp.fr.
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Spano
authors.affiliation: Department of Radiation Oncology, Institut Paoli Calmettes, Marseille 13009, France. Philippe.METELLUS@ap-hm.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Metellus
mesh_terms: D001921:Brain / Q000473:pathology* / Q000528:radiation effects*; D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary* / Q000628:therapy; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy / Q000379:methods; D016371:Cranial Irradiation / Q000379:methods; D005260:Female; D006801:Humans; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D011838:Radiation-Sensitizing Agents